SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain

Author(s): Takayuki Nakagawa, Shuji Kaneko

Journal Name: Current Molecular Pharmacology

Volume 6 , Issue 2 , 2013

Become EABM
Become Reviewer
Call for Editor


The solute carrier family 1 (SLC1) consists of two neutral amino acid transporters and five high-affinity excitatory amino acid transporters (EAAT1-5). EAATs are expressed in glial cells (EAAT1/GLAST and EAAT2/GLT-1), neurons (EAAT3/EAAC1 and EAAT4), and the retina (EAAT5), where they precisely regulate extracellular glutamate levels at both synaptic and extrasynaptic sites. EAATs play essential roles in the maintenance of normal excitatory synaptic transmission, protection of neurons from the excitotoxic action of excessive glutamate, and regulation of glutamatemediated neuroplasticity. Therefore, dysfunction of EAATs can cause abnormal excitatory synaptic transmission, neuronal excitotoxicity, and the exaggeration of neuroplasticity-based events. EAAT dysfunction has been implicated in a variety of neurodegenerative and neurological diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, ischemia, and epilepsy. Recent evidence suggests that abnormalities of EAATs contribute to the pathogenesis of psychiatric diseases and pathological pain. The present review will briefly discuss novel findings on the roles of EAATs in the pathogenesis of psychiatric diseases such as schizophrenia, mood disorders, and drug dependence/ addiction, and pathological pain, as well as the potential of EAATs as therapeutic targets.

Keywords: Astrocyte, drug addiction, EAAT1, EAAT2, glutamate transporter, mood disorders, pathological pain, schizophrenia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 24 July, 2013
Page: [66 - 73]
Pages: 8
DOI: 10.2174/18744672113069990033
Price: $65

Article Metrics

PDF: 35